PANCREATIC ADENOCARCINOMA METASTATIC
Clinical trials for PANCREATIC ADENOCARCINOMA METASTATIC explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC ADENOCARCINOMA METASTATIC trials appear
Sign up with your email to follow new studies for PANCREATIC ADENOCARCINOMA METASTATIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for pancreatic cancer: targeted drug combo enters phase 3 trial
Disease control Recruiting nowThis study tests a new drug called daraxonrasib, which targets a common cancer-driving protein (RAS). It is given alone or with standard chemotherapy to people with metastatic pancreatic cancer that has spread. The goal is to see if the new drug helps people live longer or slows …
Matched conditions: PANCREATIC ADENOCARCINOMA METASTATIC
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 26, 2026 12:05 UTC
-
Last-Resort drug access opens for pancreatic cancer patients
Disease control AVAILABLEThis program provides the experimental drug daraxonrasib to adults with advanced pancreatic cancer that has spread and worsened after prior treatments. It is for patients who have no good standard options and cannot join a daraxonrasib clinical trial. The goal is to offer a poten…
Matched conditions: PANCREATIC ADENOCARCINOMA METASTATIC
Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 26, 2026 12:04 UTC
-
Electric field therapy joins chemo in fight against pancreatic cancer
Disease control Recruiting nowThis study tests a device that sends low-intensity electric fields (TTFields) to tumors, combined with standard chemotherapy, in people with metastatic pancreatic cancer. The goal is to see if adding the device is safe and helps control the disease. About 30 adults will take part…
Matched conditions: PANCREATIC ADENOCARCINOMA METASTATIC
Phase: PHASE1, PHASE2 • Sponsor: Clinica Universidad de Navarra, Universidad de Navarra • Aim: Disease control
Last updated May 26, 2026 12:03 UTC
-
Could a stem cell boost help fight hard-to-treat cancers?
Disease control Recruiting nowThis early-stage trial is testing a new treatment for people with metastatic pancreatic or breast cancer that has spread. The treatment combines chemotherapy drugs with high-dose vitamin C and the patient's own stem cells to try to overcome drug resistance. The main goal is to ch…
Matched conditions: PANCREATIC ADENOCARCINOMA METASTATIC
Phase: PHASE1 • Sponsor: General Oncology, Inc. • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New hope for pancreatic cancer: targeted drug combo enters human trials
Disease control Recruiting nowThis early-phase trial tests a new targeted drug (OMTX705) combined with standard chemotherapy and an immunotherapy for people with advanced or metastatic pancreatic cancer. The study aims to find the safest dose and see if the combination helps shrink tumors or control the disea…
Matched conditions: PANCREATIC ADENOCARCINOMA METASTATIC
Phase: PHASE1 • Sponsor: Oncomatryx Biopharma S.L. • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New hope for pancreatic cancer: drug combo trial launches
Disease control Recruiting nowThis study tests whether adding the experimental drug atebimetinib to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will be randomly assigned to receive either the new combination or standard ch…
Matched conditions: PANCREATIC ADENOCARCINOMA METASTATIC
Phase: PHASE3 • Sponsor: Immuneering Corporation • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New combo therapy aims to halt pancreatic cancer progression
Disease control Recruiting nowThis study tests whether combining niraparib and ipilimumab can slow tumor growth in people with metastatic pancreatic cancer that has not worsened after initial platinum chemotherapy. About 68 adults will be randomly assigned to receive either the drug combo or standard chemothe…
Matched conditions: PANCREATIC ADENOCARCINOMA METASTATIC
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated May 06, 2026 16:03 UTC